Current trends in antiepileptic drug therapy

Epilepsia

Volumn 44, Issue SUPPL. 4, 2003, Pages 41-47

  Perucca, Emilio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

Antiepileptic drugs; Drug treatment; Epilepsy

Indexed keywords

ANTICONVULSIVE AGENT; BRIVARACETAM; CARABERSAT; CARBAMAZEPINE; CARBAMIC ACID 2 (2 CHLOROPHENYL) 2 HYDROXYETHYL ESTER; CONANTOKIN G; ETIRACETAM; FELBAMATE; GABAPENTIN; HARKOSERIDE; LAMOTRIGINE; OXCARBAZEPINE; PREGABALIN; RETIGABINE; RUFINAMIDE; SAFINAMIDE; SPD 421; TALAMPANEL; TIAGABINE; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VALROCEMIDE; VIGABATRIN; ZONISAMIDE;

ADD ON THERAPY; BIPOLAR DISORDER; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DISEASE EXACERBATION; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG MONITORING; DRUG TOLERABILITY; ELECTROENCEPHALOGRAM; EMPIRICISM; EPILEPSY; EPILEPTOGENESIS; EYE TOXICITY; GENETIC MARKER; HUMAN; INFANTILE SPASM; MEDICAL PRACTICE; MONOTHERAPY; NEUROLOGIC DISEASE; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; RISK FACTOR; TUBEROUS SCLEROSIS;

EID: 0038153877     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1528-1157.44.s4.1.x     Document Type: Conference Paper

References (61)

1. Beghi E, Perucca E. The management of epilepsy in the 1990s: acquisitions, uncertainties, and perspectives for future research. Drugs 1995;49:680-94.
2. Shorvon SD, Reynolds EH. Reduction in polypharmacy for epilepsy. Br Med J 1979;2:1023-5.
3. Reynolds EH, Shorvon SD. Monotherapy or polytherapy for epilepsy? Epilepsia 1981;81:1-10.
4. Perucca E, Dulac O, Shorvon S, Tomson T. Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation. CNS Drugs 2001;15:609-21.
5. Mattson RH, Cramer JA, Collins JF, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. N Engl J Med 1985;313:145-51.
6. Perucca E. The clinical pharmacology and therapeutic use of the new antiepileptic drugs. Fundam Clin Pharmacol 2001;15:405-17.
7. Perucca E, Beghi E, Dulac O, et al. Assessing risk to benefit ratio in antiepileptic drug therapy. Epilepsy Res 2000;41:107-39.
8. Perucca E. Principles of pharmacotherapy of the epilepsies. In: Asbury AK, McKhann G, McDonald WI, Goadsby PJ, McArthur JC, eds. Diseases of the nervous system: clinical neuroscience and therapeutic principles. 3rd ed. Cambridge, UK: Cambridge University Press, 2002:1301-12.
9. Perucca E. Pharmacoresistance in epilepsy. How should it be defined? CNS Drugs 1998;10:171-9.
10. Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med 2000;342:314-9.
11. Walker MC, Sander JWAS. The impact of the new antiepileptic drugs on the prognosis of epilepsy. Seizure freedom should be the ultimate goal. Neurology 1996;46:912-4.
12. Perucca E. What can we learn from clinical trials of new anticonvulsant drugs in epilepsy? Eur J Pain 2002;6(suppl A):35-44.
13. Walker MC, Sander JWAS. Difficulties in extrapolating from clinical trials to clinical practice: the case of antiepileptic drugs. Neurology 1997;49:333-7.
14. Perucca E, Tomson T. Monotherapy trials with the new antiepileptic drugs: study designs, practical relevance and ethical implications. Epilepsy Res 1999;33:247-62.
15. First Seizure Trial Group. Randomized clinical trial of the efficacy of antiepileptic drugs in reducing the risk of relapse after first unprovoked tonic-clonic seizure. Neurology 1993;43:478-83.
16. Musicco M, Beghi E, Solari A, Viani F. Treatment of first tonicclonic seizure does not improve the prognosis of epilepsy. First Seizure Trial Group (FIRST Group). Neurology 1997;49:991-8.
17. Jannuzzi G, Cian P, Fattore G, et al. A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. Epilepsia 2000;41:222-30.
18. Temkin NR. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia 2001;42:515-24.
19. Berg AT, Shinnar S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology 1994;44:601-8.
20. De Santis A. Diffusion of antiepileptic prophylaxis in Italy, In: Murri L, Parenti G, Annegers JF, eds. Pharmacological prophylaxis for post-traumatic epilepsy. Pisa, Italy: Pacini Ed, 1991:95-112.
21. De Santis A, Villani R, Sinisi M, Stocchetti N, Perucca E. Add-on phenytoin fails to prevent early seizures after surgery for supratentorial brain tumors: a randomized controlled study. Epilepsia 2002;43:175-82.
22. Medical Research Council Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 1991;337:1175-80.
23. American Academy of Neurology. Quality Standards Subcommittee. Practice parameter: management issues for women with epilepsy. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Epilepsia 1998;39:1226-31.
24. American Academy of Pediatrics. Committee on Quality Improvement, Subcommittee on Febrile Seizures. Practice parameter: long-term treatment of the child with simple febrile seizures. Pediatrics 1999;103:1307-9.
25. French J, Smith M, Faught E, Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 1999;52:1540-5.
26. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of epilepsy in adults. Edinburgh, Scotland, 1997.
27. Claxton K, Sculpher M, Drummond M. A rational framework for decision making by the National Institute for Clinical Excellence (NICE). Lancet 2002;360:711-5.
28. Beghi E, Citterio A, Cornelio F, Filippini G, Grill R, Liberati A. Practice guidelines: a more rational approach to diagnosis and treatment and a more effective use of health care resources. Ital J Neurol Sci 1998;19:120-3.
29. Chiron C, Dumas C, Jambaqué I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. Epilepsy Res 1997;26:389-95.
30. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. Epilepsia 1997;38:1270-4.
31. Claes L, del Bavero J, Ceulemans B, Lagae L, Van Broeckhoven C, De Jonghe P. De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy. Am J Hum Genet 2001;68:1327-32.
32. Guerrini R, Dravet C, Genton P, Belmonte A, Kaminska A, Dulac O. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia 1998;39:508-12.
33. Perucca E. Patient-tailored antiepileptic drug therapy: predicting response to antiepileptic drugs. In: Kaneko S, Motomura S, Tateishi T et al, eds. Pharmacogenetics - tailor-made pharmacotherapy. Amsterdam: Elsevier, 2002:105-16.
34. Tallis R, Boon P, Perucca E, Stephen L. Epilepsy in the elderly: management issues. Epileptic Disord 2002;4(suppl 2):33-40.
35. Johnson JE, Pryor FM, Ramsay ER, et al. Recruiting older patients into randomized controlled trials: an update [Abstract]. Epilepsia. 2002;43(suppl 7):165.
36. Backonja M, Beydoun A, Edwards KR, et al. Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998;280:1831-6.
37. Silberstein DD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996;36:547-55.
38. Shelton MD, Calabresse JR. Lamotrigine: efficacy and use in psychiatric disorders. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia: Raven Lippincott, 2002:403-7.
39. Brodie MJ, Chadwick DJ, Anhut H, et al. Gabapentin versus lamotrigine monotherapy: a double-blind comparison in newly diagnosed epilepsy. Epilepsia 2002;43:993-1000.
40. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996;42:531-43.
41. Brodie MJ, Overstall PW, Giorgi L, et al. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Res 1999;37:81-7.
42. Palmieri C. Canger R. Teratogenic potential of the newer antiepileptic drugs: what is known and how should this influence prescribing? CNS Drugs 2002;16:755-64.
43. Beghi E, Annegers JF. Pregnancy registries in epilepsy. Epilepsia 2001;42:1422-5.
44. Battino D, Mamoli D, Messina S, Perucca E, Tomson T. Malformations in the offspring of pregnant women with epilepsy. Presentation of an intemational registry of antiepileptic drugs and pregnancy (EURAP). Rev Neurol 2002;34:476-80.
45. Perucca E. Pharmacological principles as a basis for polytherapy. Acta Neurol Scand 1995;162(suppl):31-4.
46. Kwan P, Brodie MJ. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000;9:464-8.
47. Deckers CL, Czuczwar SJ, Hekster YA, et al. Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia 2000;41:1364-74.
48. Perucca E, Levy RH. Combination therapy and drug interactions. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia: Raven Lippincott, 2002:96-102.
49. Barcs G, Walker EB, Elger CE, et al. Oxcarbazepine placebo-controlled, dose-ranging trial in refractory partial epilepsy. Epilepsia 2000;41:1597-607.
50. Besag FM, Berry DJ, Pool F, Newbury JE, Subel B. Carbamazepine toxicity with lamotrigine: pharmacokinetic of pharmacodynamic interaction? Epilepsia 1998;39:183-7.
51. Brodie MJ, Yuen AWC. Lamotrigine substitution study: evidence for synergism with sodium valproate. 105 Study Group. Epilepsy Res 1997;26:423-32.
52. Pisani F, Oteri G, Russo MF, Di Perri R, Perucca E, Richens A. The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction. Epilepsia 1999;40:1141-6.
53. Craig J, Russell A, Parsons L, et al. The UK Epilepsy and Pregnancy Registry: update of results 1996-2002 [Abstract]. Epilepsia 2002;43(suppl 8):56.
54. Tennis P, Eldridge RR, and the International Lamotrigine Pregnancy Registry Scientific Advisory Committee. Preliminary results on pregnancy outcomes in women using lamotrigine. Epilepsia 2002;43:1161-7.
55. Gatti G, Perucca E. Challenges in the pharmacotherapy of the epilepsies. Expert Rev Neurother 2002;2:439-42.
56. Bialer M, Walker MC, Sander JW. Pros and cons for the development of new antiepileptic drugs. CNS Drugs 2002;16:285-9.
57. Bialer M, Johannessen SI, Kupferberg HJ, Levy RH, Loiseau P, Perucca E. Progress report on new antiepileptic drugs: a summary of the Sixth Eilat Conference (EILAT VI). Epilepsy Res 2002;51:31-71.
58. Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs 2002;16:579-93.
59. Le Van Quyen M, Martinerie J, Navarro V, et al. Anticipation of epileptic seizures from standard EEG recordings. Lancet 2001;357:183-8.
60. Stein AG, Eder HG, Blum DE, Drachev A, Fisher RS. An automated drug delivery system for focal epilepsy. Epilepsy Res 2000;39:103-14.
61. Temkin NR, Jarell AD, Anderson GD. Antiepileptogenic agents: how close are we? Drugs 2001;61:1045-55.